An Observational Study of the Safety and Effectiveness of Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Treated in Argentina
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 14 Jun 2017 Planned primary completion date changed from 1 Nov 2019 to 15 Nov 2022.
- 14 Jun 2017 Planned initiation date changed from 1 Mar 2017 to 18 Aug 2017.
- 02 Mar 2017 New trial record